stockrow
Friday 6 November 2026
Export TTOO’s income statement to Excel — free account
T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
0.00
0.00
NaN
Follow TTOO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM Sep ’24 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 4 | 5 | 11 | 8 | 18 | 28 | 22 | 7 | 8 | +8.4% | 11 | 23 | 33 | +66.7% | |
| Gross margin, % | — | — | (68.43) | (157.78) | (46.70) | (101.12) | (17.37) | 26.21 | 5.81 | (113.58) | (76.76) | (45.1) pt | ||||||
| EBT | — | — | (55) | (62) | (51) | (59) | (47) | (49) | (62) | (50) | (43) | (1.3%) | ||||||
| EBT margin, % | — | — | (1,343.24) | (1,337.93) | (487.17) | (707.93) | (258.12) | (175.50) | (277.98) | (696.19) | (559.52) | +647.1 pt | ||||||
| Net income | — | — | (55) | (62) | (51) | (59) | (47) | (49) | (62) | (50) | (43) | (1.3%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 784.62 | 729.06 | 1,296.30 | 915.93 | 746.09 | 882.33 | 437.35 | 2.76 | 0.43 | (55.4%) | |||||
| Earnings | — | — | (10,500.00) | (9,449.30) | (6,300.00) | (6,500.00) | (1,950.00) | (1,550.00) | (1,228.00) | (19.19) | (5.95) | (59.4%) | ||||||
| Cash flow | — | — | (8,931.15) | (7,455.94) | (4,955.31) | (4,984.73) | (1,778.40) | (1,222.45) | (992.73) | (18.44) | (2.05) | (58.7%) | ||||||
| Capex | — | — | (1,055.19) | (386.87) | (73.21) | (83.63) | (32.92) | (14.47) | (6.65) | (0.07) | 0.00 | (74.5%) | ||||||
| Free cash flow | — | — | (9,986.35) | (7,842.81) | (5,028.52) | (5,068.35) | (1,811.32) | (1,236.92) | (999.37) | (18.52) | (2.05) | (59.3%) | ||||||
| Book value | — | — | 7,565.00 | 209.38 | 1,405.80 | (3,736.81) | 359.09 | (405.75) | (777.55) | (10.74) | (0.65) | n/m | ||||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 10 | +143.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | 33.33 | 30.38 | 11.61 | 6.39 | 8.31 | 2.93 | 0.37 | 1.96 | 0.00 | 11.9 | ||||||
| P/B | — | — | 3.46 | 105.79 | 10.71 | 0.00 | 17.27 | 0.00 | 0.00 | 0.00 | 0.00 | 17.2 | ||||||
| EV/Sales | — | — | 25.19 | 21.80 | 6.82 | 5.29 | 8.48 | 3.48 | 2.13 | 6.75 | 6.26 | 10.0 | ||||||
| EV/FCF | — | — | (1.98) | (2.03) | (1.76) | (0.96) | (3.49) | (2.48) | (0.93) | (1.00) | (1.31) | (1.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (46) | (48) | (40) | (45) | (43) | (39) | (51) | (48) | (37) | +0.5% | |||||
| Capex | — | — | (5) | (2) | (1) | (1) | (1) | 0 | 0 | 0 | 0 | (38.1%) | ||||||
| Free cash flow | — | — | (52) | (50) | (41) | (46) | (44) | (39) | (51) | (48) | (37) | (1.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 66 | (7) | 4 | (42) | 44 | 33 | 9 | (31) | (15) | n/m | |||||
| Net debt | — | — | (33) | (40) | (50) | (9) | 3 | 16 | 39 | (16) | (2) | (10.2%) | ||||||
| Shareholders’ equity | — | — | 39 | 1 | 11 | (34) | 9 | (13) | (40) | (28) | (12) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (62.14) | (86.45) | (85.85) | (127.17) | (87.01) | (70.54) | (131.41) | (144.89) | (140.00) | (82.8) pt | |||||
| ROIC | — | — | (517.39) | 0.00 | 0.00 | 0.00 | (219.57) | (1,015.05) | 0.00 | 0.00 | 0.00 | +517.4 pt | ||||||
| ROE | — | — | (127.04) | (306.94) | (803.85) | 521.76 | 370.25 | 2,357.72 | 237.20 | 147.96 | 277.61 | +275.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 178 | 161 | 153 | 151 | 148 | 182 | 158 | 113 | — | (6.3%) | |||||
| Revenue/emp, $m | — | — | 0.02 | 0.03 | 0.07 | 0.06 | 0.12 | 0.15 | 0.14 | 0.06 | — | +15.7% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2024 · fundamentals updated 26 Oct 2026
T2 Biosystems, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MDXH MDxHealth SA | $14.4M | — (loss-making) | — (loss-making) | +12.01% (above 0%: growing) | n/m | −200.20% (below 0%: shrinking) | 65.75% | (18.74%) | Compare |
| NDRA ENDRA Life Sciences Inc. | $7.5M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | |
| XWEL XWELL, Inc. | $6.1M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $3.3M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | Compare |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | Compare |
| ADVB Advanced Biomed Inc. | $3.1M | 0.3× | — | — | n/m | −101.33% (below 0%: shrinking) | — | 0.00% | Compare |
| AWHL Aspira Women's Health Inc. | $2.4M | — (loss-making) | — (loss-making) | −14.89% (below 0%: shrinking) | n/m | −24.57% (below 0%: shrinking) | 55.28% | (89.69%) | Compare |
| ISPC iSpecimen Inc. | $2.0M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | Compare |
| Median of peers | $3.3M | — | — | −7.08% | — | −33.80% | 41.26% | (59.57%) |